| __timestamp | Alnylam Pharmaceuticals, Inc. | Xenon Pharmaceuticals Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 190249000 | 11768000 |
| Thursday, January 1, 2015 | 276495000 | 15152000 |
| Friday, January 1, 2016 | 382392000 | 19828000 |
| Sunday, January 1, 2017 | 390635000 | 25573000 |
| Monday, January 1, 2018 | 505420000 | 23634000 |
| Tuesday, January 1, 2019 | 655114000 | 38845000 |
| Wednesday, January 1, 2020 | 654819000 | 50523000 |
| Friday, January 1, 2021 | 792156000 | 75463000 |
| Saturday, January 1, 2022 | 883015000 | 105767000 |
| Sunday, January 1, 2023 | 1004415000 | 167512000 |
| Monday, January 1, 2024 | 1126232000 |
Unlocking the unknown
In the ever-evolving world of pharmaceuticals, innovation is the key to staying ahead. Alnylam Pharmaceuticals, Inc. and Xenon Pharmaceuticals Inc. have been at the forefront of this race, with their research and development (R&D) spending reflecting their commitment to innovation. Over the past decade, Alnylam has consistently outpaced Xenon in R&D investment, with a staggering 428% increase from 2014 to 2023. In 2023 alone, Alnylam's R&D expenses reached over $1 billion, marking a significant leap from $190 million in 2014. In contrast, Xenon, while showing growth, increased its R&D spending by 1,324% over the same period, reaching $168 million in 2023. This data highlights the strategic priorities of these companies, with Alnylam focusing on maintaining its lead in innovation, while Xenon is rapidly scaling its efforts to catch up. The trend underscores the dynamic nature of the pharmaceutical industry, where R&D is not just an expense but a critical investment in future breakthroughs.
AbbVie Inc. or Xenon Pharmaceuticals Inc.: Who Invests More in Innovation?
Research and Development Investment: Novartis AG vs Xenon Pharmaceuticals Inc.
Research and Development Expenses Breakdown: Alnylam Pharmaceuticals, Inc. vs Summit Therapeutics Inc.
Comparing Innovation Spending: Alnylam Pharmaceuticals, Inc. and Viatris Inc.
Research and Development Investment: Alnylam Pharmaceuticals, Inc. vs Arrowhead Pharmaceuticals, Inc.
R&D Spending Showdown: Alnylam Pharmaceuticals, Inc. vs Geron Corporation
Research and Development Investment: United Therapeutics Corporation vs Xenon Pharmaceuticals Inc.
Halozyme Therapeutics, Inc. vs Xenon Pharmaceuticals Inc.: Strategic Focus on R&D Spending
R&D Insights: How TG Therapeutics, Inc. and Xenon Pharmaceuticals Inc. Allocate Funds
R&D Insights: How Verona Pharma plc and Xenon Pharmaceuticals Inc. Allocate Funds
Comparing Innovation Spending: Xenon Pharmaceuticals Inc. and Dynavax Technologies Corporation
Research and Development: Comparing Key Metrics for Xenon Pharmaceuticals Inc. and Wave Life Sciences Ltd.